Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

Targretin Capsules (2012)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης Eisai Ltd
Διεύθυνση Teva UK Limited, Field House, Station Approach, Harlow, Essex, CM20 2FB
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Name of the medicinal product

Targretin 75 mg soft capsules.

Qualitative and quantitative composition

Each capsule contains 75 mg of bexarotene. For a full list of excipients, see section 6.1.

Pharmaceutical form

Soft capsule. Off-white capsule, containing a liquid suspension and imprinted with Targretin.

Therapeutic indications

Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.

Posology and method of administration

Bexarotene therapy should only be initiated and maintained by physicians experienced in the treatment of patients with CTCL. The recommended initial dose is 300 mg/m<sup>2</sup>/day. Targretin capsules ...

Contraindications

Known hypersensitivity to bexarotene or to any of the excipients of the product. Pregnancy and lactation. Women of child-bearing potential without effective birth-control measures. History of pancreatitis. ...

Special warnings and precautions for use

General: Targretin capsules should be used with caution in patients with a known hypersensitivity to retinoids. No clinical instances of cross-reactivity have been noted. Patients receiving bexarotene ...

Special warnings and precautions for use

Do not store above 30°C. Keep the bottle tightly closed.

Interaction with other medicinal products and other forms of interaction

Effects of other substances on bexarotene: no formal studies to evaluate interactions with bexarotene have been conducted. On the basis of the oxidative metabolism of bexarotene by cytochrome P450 3A4 ...

Pregnancy and lactation

Pregnancy There are no adequate data from the use of bexarotene in pregnant women. Studies in animals have shown reproductive toxicity. Based on the comparison of animal and patient exposures to bexarotene, ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, dizziness and visual difficulties have been reported in patients taking Targretin. Patients who experience ...

Undesirable effects

The safety of bexarotene has been examined in clinical studies of 193 patients with CTCL who received bexarotene for up to 118 weeks and in 420 non-CTCL cancer patients in other studies. In 109 patients ...

Overdose

No clinical experience with an overdose of Targretin has been reported. Any overdose should be treated with supportive care for the signs and symptoms exhibited by the patient. Doses up to 1000 mg/m²/day ...

Pharmacodynamic properties

Pharmacotherapeutic Group: other antineoplastic agents ATC code: L01XX25 Bexarotene is a synthetic compound that exerts its biological action through selective binding and activation of the three RXRs: ...

Pharmacokinetic properties

Absorption/dose proportionality: pharmacokinetics were linear up to a dose of 650 mg/m². Terminal elimination half-life values were generally between one and three hours. Following repeat once daily dose ...

Preclinical safety data

Carcinogenesis, mutagenesis, impairment of fertility Bexarotene is not genotoxic. Carcinogenicity studies have not been conducted. Fertility studies have not been conducted; however, in sexually immature ...

List of excipients

Capsule content: Macrogol Polysorbate Povidone Butylated hydroxyanisole Capsule shell: Gelatin Sorbitol special-glycerin blend (glycerin, sorbitol, sorbitol anhydrides (1,4-sorbitan), mannitol and water) ...

Incompatibilities

Not applicable.

Shelf life

3 years.

Nature and contents of container

High-density polyethylene bottles with child-resistant closures containing 100 capsules.

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

Eisai Ltd. European Knowledge Centre Mosquito Way Hatfield Hertfordshire AL10 9SN United Kingdom

Marketing authorization number(s)

EU/1/01/178/001

Date of first authorization / renewal of the authorization

Date of first authorisation: 29 March 2001 Date of latest renewal: 29 March 2006

Date of revision of the text

6th Apr 2009
Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.